within Pharmacolibrary.Drugs.ATC.J;

model J01MA16
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.96,
    Cl             = 0.00012516666666666668,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0012,
    k12             = 5.2,
    k21             = 5.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01MA16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gatifloxacin is a fourth-generation fluoroquinolone antibiotic formerly used to treat a variety of bacterial infections including respiratory tract infections, urinary tract infections, and conjunctivitis. It has been withdrawn from many markets (including the US and Europe) due to concerns of dysglycemia (blood sugar disturbances), but may still be used in some countries and as an ophthalmic preparation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic profile in healthy adult volunteers following a single oral 400 mg dose.</p><h4>References</h4><ol><li><p>Perry, CM, et al., &amp; Lamb, HM (1999). Gatifloxacin. <i>Drugs</i> 58(4) 683–698. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199958040-00010&quot;>10.2165/00003495-199958040-00010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10551438/&quot;>https://pubmed.ncbi.nlm.nih.gov/10551438</a></p></li><li><p>Kikuchi, J, et al., &amp; Nishimura, M (2007). Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage. <i>Clinical therapeutics</i> 29(1) 123–130. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2007.01.005&quot;>10.1016/j.clinthera.2007.01.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17379052/&quot;>https://pubmed.ncbi.nlm.nih.gov/17379052</a></p></li><li><p>Grasela, DM, et al., &amp; LaCreta, FP (2000). Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment. <i>Pharmacotherapy</i> 20(6 Pt 2) 87S–94S. DOI:<a href=&quot;https://doi.org/10.1592/phco.20.8.87s.35187&quot;>10.1592/phco.20.8.87s.35187</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10850525/&quot;>https://pubmed.ncbi.nlm.nih.gov/10850525</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01MA16;
